Stryker to sell OP-1 to Olympus to $60M for all bone applications (news from Dec 2010)
The Forecast Calls for Pain (The Spine Blogger)
INSIGHT-Anatomy of a costly biotech deal for Olympus (Reuters)
* $60 mln purchase of Stryker assets may cost 50 pct more
* Olympus made $25 mln loan to NY firm to break JV deal
* Loan would need to be written off, ex-CEO told
* Olympus, Viscogliosi, Stryker decline comment
By Paritosh Bansal, Kirstin Ridley and Kevin Krolicki
Oct 26 (Reuters) - Soon after paying a record-setting fee to close a now-controversial takeover in the spring of 2010, Japanese camera and endoscope maker Olympus Corp was back out shopping for another deal.
Once again, it turned to a New York-based advisory firm outside the dealmaking mainstream and once again the Japanese company ended up paying an out-sized amount to complete a tangled deal that has come under scrutiny, internal company documents show.
Olympus agreed in December last year to buy the rights to a biotech remedy intended to help regenerate human bone from medical device maker Stryker Corp for $60 million.
But the documents reviewed by Reuters show that the deal may end up costing th...
